French researchers have discovered a peptide called Spadin—originally developed as an antidepressant—that may restore cognitive function in Alzheimer’s patients by targeting four key mechanisms simultaneously. Tests on mice show reduced amyloid plaques, lowered brain inflammation, improved neuron communication, and partial recovery of memory and learning. The breakthrough, published in June 2026, marks a radical shift from decades of failed amyloid-focused therapies.
How Spadin Works: A Four-Pronged Attack on Alzheimer’s
Spadin, a peptide derived from blocking the TREK-1 ion channel in neurons, wasn’t designed to treat Alzheimer’s. Its origins trace back to research at the CNRS and Université Côte d’Azur’s neuroscience lab in Valbonne, where scientists were studying depression. But when they tested Spadin on mice with Alzheimer-like symptoms, they found it simultaneously reduced amyloid plaques, cut brain inflammation, improved neuron signaling, and even restored some lost cognitive functions.
The most striking result? Mice treated with Spadin navigated labyrinths faster and retained more information than untreated controls—despite still having amyloid buildup. This suggests Spadin works through a different pathway than existing amyloid-targeting drugs like lecanemab or donanemab, which only slow cognitive decline without restoring function. “The combination of these three effects is what makes this so promising,” said researchers in Cell Reports Medicine.
The French-Swiss Divide: Two Separate Breakthroughs, One Disease
While French researchers were uncovering Spadin’s potential, a separate team at ETH Zurich identified a different molecular target: an enzyme called GRK2. Unlike Spadin, which targets neuron communication, the Swiss team found that GRK2’s malfunctioning form clogs mitochondria—the brain’s energy centers—accelerating neuron death. Their compound, “Compound 10,” prevented GRK2 from aggregating, preserving mitochondrial function and slowing dementia progression in mice.
Both approaches share a critical distinction from past Alzheimer’s research: they don’t just attack symptoms like amyloid plaques. Instead, they target root causes—inflammation (Spadin) and cellular energy failure (Compound 10). “Alzheimer’s isn’t just one problem,” said pharmacologist Ursula Quitterer of ETH Zurich. “It’s a cascade of failures, and we need treatments that address multiple links in that chain.”
AETA: The Missing Piece That Explains Why Women Are More Vulnerable
Meanwhile, a third French team at the Institut de Pharmacologie Moléculaire et Cellulaire (IPMC) uncovered a peptide called AETA—elevated in Alzheimer’s patients’ hippocampi and prefrontal cortices—that may explain why women develop the disease at higher rates. Their study found AETA disrupts synaptic function and NMDA receptors (critical for learning), with female mice showing severe memory deficits absent in males.
“Chez les malades, l’AETA est très nettement augmenté dans l’hippocampe et le cortex préfrontal, deux régions impliquées dans la mémoire et les fonctions cognitives.”
This discovery could redefine risk assessment. If AETA’s role is confirmed in humans, it might explain why women—who represent two-thirds of Alzheimer’s cases—experience faster cognitive decline. The IPMC team’s work, published in Acta Neuropathologica, suggests AETA could become a biomarker for early diagnosis or a new drug target.
Why This Matters: The End of the Amyloid Obsession?
For 30 years, pharmaceutical companies chased amyloid plaques as the primary cause of Alzheimer’s. The results? Two approved drugs (lecanemab and donanemab) that modestly slow decline—but at the cost of brain swelling and microbleeds. The new research suggests amyloid may not be the root problem, but a symptom of deeper dysfunction.
Spadin and Compound 10 represent a paradigm shift: instead of clearing plaques, they restore neuron function. “We’re not just treating Alzheimer’s,” said Inserm researchers. “We’re giving the brain a chance to heal itself.”
What Happens Next: From Mice to Humans
The next phase? Clinical trials. Both Spadin and Compound 10 showed promise in mice, but translating animal results to humans is notoriously difficult. The French team plans to test Spadin’s safety in healthy volunteers first, while the Swiss group will expand their human tissue studies before considering trials.
Timing is critical. With nearly 1 million French Alzheimer’s patients and 225,000 new cases diagnosed yearly, even a modestly effective treatment could transform care. But experts warn: “Don’t expect miracles,” said a neurology professor at Top Santé. “We’re still years from a cure, but for the first time, we’re seeing real progress.”
One thing is clear: the amyloid era may be over. The future of Alzheimer’s treatment lies in molecules like Spadin and Compound 10—targeting not just plaques, but the brain’s fundamental breakdown.
Find more reporting in our Health section.
